within Pharmacolibrary.Drugs.ATC.M;

model M09AX03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.56,
    Cl             = 0.08,
    adminDuration  = 600,
    adminMass      = 0.04,
    adminCount     = 1,
    Vd             = 0.109,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.005849999999999999,
    Tlag           = 10.200000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Ataluren is a small molecule drug designed to promote ribosomal readthrough of nonsense mutations in genetic diseases. It is indicated for the treatment of Duchenne muscular dystrophy (DMD) caused by nonsense mutations in the dystrophin gene and has conditional approval in some countries, such as the EU, for ambulatory patients aged two years and older.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for ambulatory male patients (children and adults) with Duchenne muscular dystrophy, after single and multiple oral doses.</p><h4>References</h4><ol><li>Ronald Kong, Oscar L Laskin, Diksha Kaushik, Fengbin Jin, Jiyuan Ma, Joseph McIntosh, Marcio Souza, Neil Almstead,Ataluren Pharmacokinetics in Healthy Japanese and Caucasian Subjects.,Clinical pharmacology in drug development,2019<a href='https://pubmed.ncbi.nlm.nih.gov/30629861/'>https://pubmed.ncbi.nlm.nih.gov/30629861/</a></li><li>Sylwia Michorowska,Ataluren-Promising Therapeutic Premature Termination Codon Readthrough Frontrunner.,Pharmaceuticals (Basel, Switzerland),2021<a href='https://pubmed.ncbi.nlm.nih.gov/34451881/'>https://pubmed.ncbi.nlm.nih.gov/34451881/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end M09AX03;
